Bio-Rad Laboratories, Inc. BIO

Set alert

Price alert · BIO

All alert types
376.26 USD +10.10 +2.76%

As of Nov 3, 1:12 PM ET

Bid
375.42 × 1
Ask
376.31 × 1
369.86 Day range 376.81
241.71 52-week range 390.34
YTD
+24.18%
1 year
+20.82%
Open
369.45
Prev close
366.16
Mkt cap
10.06B
Vol
65.44K
Avg vol
254.03K
EPS
7.89
P/E
47.66
Div yield
0.00%
More statistics
Low
369.86
High
376.81
Forward P/E
37.57
Beta
1.06
Short ratio
4.17
Inst. own
91.74%
Dividend
0.00
Ex-div date
Earnings
Nov 4, 2026
50-d avg
374.80
200-d avg
313.41
1y target
335.00

3M chart

Chart tools
Interval

Events in this range
  • Aug 4, 2026Earnings: 2.62; estimate 1.75; surprise 49.71%
  • Aug 5, 2026Rating: Wells Fargo · Equal-Weight → Equal-Weight
  • Aug 5, 2026Rating: RBC Capital · Outperform → Outperform
  • Aug 5, 2026Rating: Citigroup · Neutral → Neutral
  • Aug 7, 2026Rating: RBC Capital · Outperform → Outperform
Signals (21)
NameDateAgo
SMA: BullishNov 3, 20263 hours ago
SMA: BullishNov 3, 20263 hours ago
SMA: BearishNov 2, 20261 day ago
SMA: BearishOct 30, 20264 days ago
SMA: BullishOct 27, 20261 week ago
SMA: BullishOct 26, 20261 week ago
MACD: Buy SignalOct 23, 20261 week ago
SMA: BearishOct 7, 20263 weeks ago
SMA: BearishOct 6, 20264 weeks ago
SMA: BullishOct 5, 20264 weeks ago
SMA: BullishOct 2, 20261 month ago
SMA: BearishOct 1, 20261 month ago
SMA: BearishSep 30, 20261 month ago
SMA: BullishSep 29, 20261 month ago
SMA: BearishSep 28, 20261 month ago
SMA: BullishSep 15, 20261 month ago
SMA: BearishSep 14, 20261 month ago
RSI: OverboughtSep 2, 20262 months ago
MACD: Sell SignalSep 1, 20262 months ago
RSI: OverboughtAug 19, 20262 months ago

Newest 20 of 21.

Analyst view

Consensus: hold

Hold
Price target (mean) 335.00 -11.0% downside
Target (low)
280.00
Target (mean)
335.00
Target (high)
390.00
Ratings (0m) 3 1 buy · 1 hold · 1 sell
  • Strong buy1
  • Buy0
  • Hold1
  • Sell0
  • Strong sell1

Recommendation trend

  • This month 3
  • 1 month ago 3
  • 2 months ago 5

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

BIO analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter2.232.16 – 2.292.26-1.6%649.95M-0.5%2
Next quarter3.022.74 – 3.302.51+20.3%695.40M+0.3%2
Current year9.458.85 – 10.109.92-4.7%2.57B-0.5%3
Next year9.758.75 – 10.909.45+3.1%2.62B+2.1%3

Upgrades and downgrades

The latest rating changes

BIO analyst upgrades and downgrades
DateFirmActionFromTo
Aug 7, 2026RBC CapitalMaintainedOutperformOutperform
Aug 5, 2026CitigroupMaintainedNeutralNeutral
Aug 5, 2026RBC CapitalMaintainedOutperformOutperform
Aug 5, 2026Wells FargoMaintainedEqual-WeightEqual-Weight
May 1, 2026Wells FargoMaintainedEqual-WeightEqual-Weight
Apr 7, 2026CitigroupDowngradeBuyNeutral
Feb 16, 2026Wells FargoMaintainedEqual-WeightEqual-Weight
Oct 30, 2025CitigroupMaintainedBuyBuy
Oct 30, 2025Wells FargoMaintainedEqual-WeightEqual-Weight
Aug 1, 2025RBC CapitalMaintainedOutperformOutperform
Aug 1, 2025Wells FargoMaintainedEqual-WeightEqual-Weight
Jun 9, 2025Wells FargoMaintainedEqual-WeightEqual-Weight
May 2, 2025UBSMaintainedBuyBuy
May 2, 2025CitigroupMaintainedBuyBuy
May 2, 2025RBC CapitalMaintainedOutperformOutperform
Apr 17, 2025Wells FargoMaintainedEqual-WeightEqual-Weight
Feb 12, 2025Wells FargoMaintainedEqual-WeightEqual-Weight
Jan 14, 2025RBC CapitalReiteratedOutperformOutperform
Dec 9, 2024RBC CapitalMaintainedOutperformOutperform
Oct 31, 2024CitigroupMaintainedBuyBuy
Oct 31, 2024RBC CapitalMaintainedOutperformOutperform
Oct 1, 2024CitigroupUpgradeNeutralBuy
Aug 27, 2024Wells FargoInitiated—Equal-Weight
Aug 16, 2024RBC CapitalReiteratedOutperformOutperform
Aug 2, 2024RBC CapitalMaintainedOutperformOutperform
Aug 2, 2024CitigroupMaintainedNeutralNeutral
May 8, 2024UBSMaintainedBuyBuy
Apr 3, 2024CitigroupDowngradeBuyNeutral
Feb 16, 2024UBSMaintainedBuyBuy
Feb 16, 2024RBC CapitalMaintainedOutperformOutperform